May 15, 2011
SSpecial Bulletin
 
                 
  HCV
»
»
»
»

 

Dear Reader :

I am happy to be able to tell you that a major advancement in treatment for people with chronic hepatitis C genotype 1 was approved by the Food and Drug Administration—the combination of Victrelis (boceprevir), pegylated interferon and ribavirin (Merck & Co.).

HCSP is gearing up to provide extensive updates and education to the HCV community. To this end we have updated more than 40 fact sheets and will continue to update our fact sheets and guides as more information becomes available.

A decision from the FDA about the approval of Incivek (telaprevir)—in combination with pegylated interferon plus ribavirin—is expected towards the end of the month. This will mean that people with HCV genotype 1 will have even more treatment options.

The approval of Victrelis and the pending approval of Incivek will mean that May 2011 will be a truly incredible month for people living with HCV—maybe we are finally turning the corner on this devastating disease—at least in regards to even more effective medications to treat all populations with HCV.

Alan

 

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

  HBV
»
»
»
»